ArticleCell reports. Medicine2023
Identification and multicentric validation of soluble CDCP1 as a robust serological biomarker for risk stratification of NASH in obese Chinese.
Article in Cell reports. Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- Development and clinical validation of a novel protein biomarkers-based algorithm for risk prediction and diagnosis of advanced liver fibrosis: a multi-centre study.Journal of advanced research · 2026Article
- Inflammatory Proteomic Heterogeneity Beyond Glycemia Status in Severe Obesity.International journal of molecular sciences · 2026Article
- A Five-Plasma Protein-Based Algorithm for Predicting Incident CKD in Type 2 Diabetes.Journal of the American Society of Nephrology : JASN · 2026Article
- Allyl isothiocyanate ameliorates metabolic dysfunction-associated steatotic liver diseaseWorld journal of gastroenterology · 2026Article
- Identification of modifiable plasma protein markers of cardiometabolic risk in children and adolescents with obesity.Nature communications · 2026Article
- Plasma inflammatory proteome profiles identify MASLD among children with overweight or obesity.Cardiovascular diabetology · 2025Article
- Low-Abundance Proteomics Reveal Pleiotrophin and Fibroblast Growth Factor-21 as Biomarkers of Metabolic Dysfunction-Associated Steatohepatitis.International journal of molecular sciences · 2025Article
- Association between plasma proteomic dynamic changes and metabolic outcomes in patients undergoing bariatric surgery.International journal of obesity (2005) · 2025Article
- Anti-integrin αvβ6 Autoantibodies Are Increased in Primary Sclerosing Cholangitis Patients With Concomitant Inflammatory Bowel Disease and Correlate With Liver Disease Severity.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025Article
- Common inflammatory proteins linking frailty and area-level deprivation as key drivers of cardiovascular risk in women.Communications medicine · 2025Article
- Clinical utility of glycated albumin and 1,5-anhydroglucitol in the screening and prediction of diabetes: A multi-center study.World journal of diabetes · 2025Article
- Resmetirom as an important cornerstone of multidisciplinary management of metabolic dysfunction-associated steatohepatitis.Hepatobiliary surgery and nutrition · 2025Article
- Review
- Role of metabolic dysfunction-associated fatty liver disease in atrial fibrillation and heart failure: molecular and clinical aspects.Frontiers in cardiovascular medicine · 2025Review
- Lipid profiling identifies modifiable signatures of cardiometabolic risk in children and adolescents with obesity.Nature medicine · 2025Article
- Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease.Medical review (2021) · 2024Article
- Causal relationships between the gut microbiota, inflammatory cytokines, and alcoholic liver disease: a Mendelian randomization analysis.Frontiers in endocrinology · 2024Article
- Metabolic Dysfunction-Associated Steatohepatitis Detected by Neutrophilic Crown-Like Structures in Morbidly Obese Patients: A Multicenter and Clinicopathological Study.Research (Washington, D.C.) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 13 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The definitive diagnosis of non-alcoholic steatohepatitis (NASH) currently relies on invasive and labor-intensive liver biopsy. Here, we identified soluble CUB domain-containing protein 1 (sCDCP1) as a top-ranked non-invasive biomarker for NASH using Olink-based proteomics in 238 obese individuals with liver biopsies. Both the circulating concentration and hepatic mRNA abundance of sCDCP1 were significantly elevated in patients with NASH and correlated closely with each histological feature of NASH. In the pooled multicenter validation cohort, sCDCP1 as a standalone biomarker achieved an area under the receiver operating characteristic (AUROC) of 0.838 (95% confidence interval [CI] 0.789-0.887) for diagnosing NASH, which is better than those achieved with cytokeratin-18 and other non-invasive tests. Furthermore, the C-DAG model established by the combination of sCDCP1 with diabetes, aspartate aminotransferase (AST), and gender accurately rules in and rules out both NASH and fibrotic NASH (gray zones <20%). Thus, sCDCP1-based non-invasive tests can be potentially implemented for screening and early diagnosis of NASH and for ruling out low-risk individuals to avoid unnecessary liver biopsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.